Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
The early in-vivo effects of a single anti-emetic dose of dexamethasone on innate immune cell gene expression and activation in healthy volunteers

Bain, C.R., Draxler, D.F., Taylor, R., Wallace, S., Gouldthorpe, O., Corcoran, T.B., Myles, P.S., L. Medcalf, R., Bozaoglu, K.

(2018), Anaesthesia, 955-966

DOI: 10.1111/anae.14306

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC, Cardozo M, Houze J, Li Y, Lucas B, Paras NA, Wang X, Taygerly JP, Vimolratana M, Zancanella M, Zhu L, Cajulis E, Osgood T, Sun J, Damon L, Egan RK, Greninger P, McClanaghan JD, Gong J, Moujalled D, Pomilio G, Beltran P, Benes CH, Roberts AW, Huang DC, Wei A, Canon J, Coxon A, Hughes PE

(2018), Cancer Discov, 8(12), 1582-1597

DOI: 10.1158/2159-8290.CD-18-0387

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH

(2018), Leukemia, 32(2), 303-312

DOI: 10.1038/leu.2017.243

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

Tiong IS, Reynolds J, Bradstock KF, Seymour JF, Wei AH; Australasian Leukaemia & Lymphoma Group

(2018), Blood Cancer J, 8(9), 84

DOI: 10.1038/s41408-018-0121-4

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

Yuen HLA, Low MSY, Fedele P, Kalff A, Walker P, Bergin K, Coutsouvelis J, Grigoriadis G, Spencer A

(2018), Leuk Lymphoma, 59(12), 2842-2846

DOI: 10.1080/10428194.2018.1454595

Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia

Tiong IS, Tan P, McManus J, Cummings N, Sadawarte S, Catalano J, Hills R, Wei A

(2018), Leuk Lymphoma, 59(2), 493-496

DOI: 10.1080/10428194.2017.1334122

Autoregulation of von Willebrand factor function by a disulfide bond switch

Butera D, Passam F, Ju L, Cook KM, Woon H, Aponte-SantamarÃa C, Gardiner E, Davis AK, Murphy DA, Bronowska A, Luken BM, Baldauf C, Jackson S, Andrews R, Grâter F, Hogg PJ

(2018), Sci Adv, 4(2), eaaq1477

DOI: 10.1126/sciadv.aaq1477

Mechanisms of platelet dysfunction in patients with implantable devices

Casan J, Andrews RK, Gardiner EE, Davis AK

(2018), Semin Thromb Hemost, 44(1), 43808

DOI: 10.1055/s-0037-1605572

Low T-cell responses to mitogen stimulation predicts poor survival in recipients of allogeneic hematopoietic stem cell transplantation

Yong MK, Cameron PU, Slavin MA, Cheng AC, Morrissey CO, Bergin K, Spencer A, Ritchie D, Lewin SR

(2017), Front Immunol, 8, 1506

DOI: 10.3389/fimmu.2017.01506

Basic mechanisms of platelet receptor shedding

Andrews RK, Gardiner EE

(2017), Platelets, 28(4), 319-24

DOI: 10.1080/09537104.2016.1235690

Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL)

Curtis DJ

(2017), Br J Haematol, 177(2), 169-70

DOI: 10.1111/bjh.14559

The cutting edge of platelets

Andrews RK, Gardiner EE

(2017), Platelets, 28(4), 317-8

DOI: 10.1080/09537104.2017.1338397

Accelerating early drug development: come on down under!

Wei A

(2017), Ann Oncol, 28(7), 1655-7

DOI: 10.1093/annonc/mdx101

Utility of CRISPR/Cas9 systems in hematology research

Lucas D, O'Leary HA, Ebert BL, Cowan CA, Tremblay CS

(2017), Exp Hematol, 54, 1-3

DOI: 10.1016/j.exphem.2017.06.006

Up-Regulation of the Vitamin D Pathway in Acute Myeloid Leukemia

Casan JML, Ghotb S, Morgan S, Wei AH, Ting SB

(2017), Ann Hematol Oncol, 4(3), 1141

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Dàhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B?chner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Làwenberg B, Bloomfield CD

(2017), Blood, 129(4), 424-47

DOI: 10.1182/blood-2016-08-733196

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, L?pez J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Bàttcher S, Ritgen M, Goede V, Mobasher M, Hallek M

(2017), Blood, 129(19), 2702-5

DOI: 10.1182/blood-2017-01-761973

Challenges and opportunities in protease-activated receptor drug development

Hamilton JR, Trejo J

(2017), Annu Rev Pharmacol Toxicol, 57, 349-73

DOI: 10.1146/annurev-pharmtox-011613-140016

Malaria after international travel: a GeoSentinel analysis, 2003-2016

Angelo KM, Libman M, Caumes E, Hamer DH, Kain KC, Leder K, Grobusch MP, Hagmann SH, Kozarsky P, Lalloo DG, Lim PL, Patimeteeporn C, Gautret P, Odolini S, Chappuis F, Esposito DH; GeoSentinel Network

(2017), Malar J, 16, 293

DOI: 10.1186/s12936-017-1936-3

Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabe¡adas J, Salles G, Gaulard P, Bosly A, Coiffier B

(2017), J Clin Oncol, 35(22), 2473-81

DOI: 10.1200/JCO.2017.72.6984

11 12 13 14 15